European Archives - Page 519 of 1054 - European Medical Journal

To be or to belong?

Diversity and inclusion (D&I) has become a core focus for pharma, but how can it go one step further and cultivate a culture of belonging?

Harnessing AI for Marketing ROI

we look at how AI tools can boost traditional marketing campaigns’ productivity, improve targeting, and deliver significant business value.

HBA's Laurie Cooke on Creating a Culture of Belonging

In what ways can we hold each other accountable, not just for the number of women in leadership, but how women, and especially women of colour, are represented and supported throughout the hiring pipeline?

Brexit revisited: how has the life sciences fared?

After years of tough negotiations, the UK has left the European Union. GOLD explores how pharmaceutical innovation has been affected as the UK works to replace EU resources and make use of its new-found regulatory freedom

How to build a disease awareness campaign remotely

The disruptor that is COVID-19 has turned everything upside down, including disease awareness campaigns. GOLD catches up with pharma marketing experts to see how they have adapted to their circumstances.

Talking to Emily Pegg

Dr Emily Pegg, Head of Medical Affairs UK, Takeda Oncology, discusses how pharma’s relationship with HCPs is evolving.

EMJ Podcast: New Data for the Management of AML

We discuss developments and data presented at the ASH 2020 virtual conference regarding the management of patients with acute myeloid leukaemia (AML).

Neurology CP

A Successful Treatment of Chronic Migraine with Hyperbaric Oxygen Therapy

Migraines involve intense head pain, which severely affects the activities of daily living, and is the is the third most common disease in the world…

What Factors Predict Severe Reactions from Immunotherapy?

PREDICTING which patients with cancer may be at risk of severe side effects from immunotherapy may be improved through the identification of specific risk..

Safety Tests Passed for Personalised Cancer Vaccine

VACCINE therapies for cancers have been a focus for developments in personalised medicine, and a recent Phase I trial has shown promising results…